Allogene Therapeutics Inc
(ALLO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 22 | 95 | 156 | 114,089 | 0 |
| Gross Profit | 22 | 95 | 156 | 114,089 | N/A |
| Operating Expenses | 273,221 | 327,832 | 335,692 | 294,281 | 258,243 |
| Operating Income | -273,199 | -327,737 | -335,536 | -180,192 | -258,243 |
| Interest Expense | 181 | 0 | 0 | 0 | 0 |
| Other Income | 16,233 | 472 | -4,878 | -1,859 | -58,138 |
| Pre-tax Income | -257,147 | -327,265 | -340,414 | -182,051 | -316,381 |
| Income Tax | 443 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -257,590 | -327,265 | -340,414 | -182,051 | -316,381 |
| Net Income | $-257,590 | $-327,265 | $-340,414 | $-182,051 | $-316,381 |
| EPS Basic Total Ops | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 |
| EPS Basic Continuous Ops | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 |
| EPS Diluted Total Ops | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 |
| EPS Diluted Continuous Ops | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 |
| EPS Diluted Before Non-Recurring Items | -1.24 | -2.01 | -2.32 | -1.89 | -2.08 |
| EBITDA(a) | $-267,908 | $-320,347 | $-318,350 | $-162,783 | $-247,407 |